Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q2 2018 · 10-Q
Revenue$235.00K$235.00K+44.9% vs Q2 2017 Net Income-$304.00K-$304.00KN/M vs Q2 2017 EPS Diluted-$0.01-$0.01N/M vs Q2 2017 Operating Income-$263,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$110,216N/M Margins · derivedOperating margin-111.9%+227.0 pt vs Q2 2017
Net margin-129.4%+230.7 pt vs Q2 2017
ended Sep 30, 2017 · filed Nov 17, 2017 · 48 d after period end